CordenPharma Switzerland


Managing Director:

Juerg Burger


Corden Pharma Switzerland LLC

Eichenweg 1
4410 Liestal
Switzerland

Phone:+41 61 906 59 59
Fax:+41 61 906 59 58

Get Driving Directions:

Get Directions

US Customer Service1-B Gill Street
Woburn, MA 01801
US Toll Free: +1 800 868 8208
US Toll: +1 1 781 305 3332
Fax: +1 781 305 3350
Email: contactUS@cordenpharma.com
 

Core Capabilities

Feasability Studies & Process Development

  • Experts for route scouting & process development for exclusive compounds & NCE APIs
    including key intermediates and chiral building blocks
  • Experts in developing and manufacturing APIs and other chemically synthesized materials (small and commercial scale)
  • Special expertise in lipids, peptides, carbohydrates, amino acid derivatives and other building blocks such as pseudoproline dipeptides


cGMP Manufacture

  • Active pharmaceutical ingredients (APIs)
  • Advanced key intermediates

Analytical Support
  • Analytical development and validation
  • Cleaning method development & validation

Quality & Regulatory Support
  • Stability Studies
  • Filing and Maintenance of US-DMFs, EDMFs and others


CordenPharma Switzerland Facility Capacities

Compliance Approvals

Highly cGMP focused and appropriate certificates

  • API manufacturing and Analytical Testing

 
Inspected by Authorities

  • Swissmedic (Quality System Inspections)
    • Bi-annual
    • 2011: 4 minor observations
    • 2013: 4 minor observations
    • 2015: 2 minor observations
  • US FDA (Pre-approval and Quality System Inspections)
    • 2000: 3 observations on the 483
    • 2004: 0 observations on the 483
    • 2007: 2 observations on the 483
    • 2011: 3 observations on the 483
    • 2014: 0 observations on the 483

Facility Legacy

CordenPharma Switzerland is a cGMP manufacturing facility with expertise in the production of high quality chemical intermediates and active pharmaceutical ingredients including synthetic peptides, lipids, small molecules and carbohydrates.

Formerly a business unit of Genzyme Corporation, CordenPharma Switzerland brings extensive peptide manufacturing capability while adding strength to an existing lipid development and manufacturing business within CordenPharma’s full-service CDMO platform.

History

  • 1994 Genzyme Pharmaceuticals acquired Sygena AG, a Swiss facility focused on the production of high quality chemical intermediates and active pharmaceutical ingredients
  • 1999 Sygena officially changed its name to Genzyme Pharmaceuticals
  • 2011 Genzyme Pharmaceuticals acquired by ICIG to become CordenPharma Switzerland